RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14
Design Therapeutics, Inc. -1.42% Pre
Design Therapeutics, Inc. DSGN | 12.49 12.49 | -1.42% 0.00% Pre |
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:
DSGN) with a Outperform and raises the price target from $13 to $14.
